Table 3 Summary of head and neck cancer clinical samples in genome sequencing studies
From: Genomically personalized therapy in head and neck cancer
| Study | Total samples | Oral cavity | Oropharynx | Hypopharynx | Larynx | Other primary sites | Lymph nodes | Metastatic samples | HPV-Positive | HPV-Negative |
|---|---|---|---|---|---|---|---|---|---|---|
| Stransky et al. [9] | 92 | 51 (55 %) | 15 (16 %) | 7 (8 %) | 15 (16 %) | 2 (2 %) | - | - | 13 (14 %) | 79 (86 %) |
| Agrawal et al. [10] | 32 | NK | NK | NK | NK | NK | - | - | 4 (12 %) | 28 (88 %) |
| Chung et al. [11] | 252 | 53 (21 %) | 12 (5 %) | - | 7 (3 %) | 103 (41 %) | 25 (10 %) | 80 (32 %) | 84 (33 %) | 168 (67 %) |
| Seiwert et al. [12] | 120 | 23 (19 %) | 67 (56 %) | 8 (7 %) | 19 (16 %) | 3 (2 %) | - | - | 51 (42 %) | 69 (58 %) |
| Pickering et al. [13] | 38 | 38 (100 %) | - | - | - | - | - | - | NK | NK |
| TCGA [14] | 279 | 172 (62 %) | 33 (12 %) | - | 72 (26 %) | - | - | - | 36 (13 %) | 243 (87 %) |